152 related articles for article (PubMed ID: 38212213)
1. Positron Emission Tomography/Computed Tomography in Thyroid Cancer: An Updated Review.
Chandekar KR; Satapathy S; Bal C
PET Clin; 2024 Apr; 19(2):131-145. PubMed ID: 38212213
[TBL] [Abstract][Full Text] [Related]
2.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
3. Positron Emission Tomography/Computed Tomography in Thyroid Cancer.
Bal C; Chakraborty D; Khan D
PET Clin; 2022 Apr; 17(2):265-283. PubMed ID: 35256297
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
5. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Value of
Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
[No Abstract] [Full Text] [Related]
7. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
8. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
9. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
10. Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.
Basu S; Parghane RV
PET Clin; 2017 Jan; 12(1):27-37. PubMed ID: 27863564
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
12. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of [
Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
15. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
16. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
Sakulpisuti C; Charoenphun P; Chamroonrat W
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956886
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
Fu H; Fu J; Huang J; Pang Y; Chen H
Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
[TBL] [Abstract][Full Text] [Related]
19. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]